Is bendamustine plus rituximab a suitable option for rituximab-refractory duodenal-type follicular lymphoma?

MLA

Cencini, E., et al. “Is Bendamustine plus Rituximab a Suitable Option for Rituximab-Refractory Duodenal-Type Follicular Lymphoma?” Acta Gastro-Enterologica Belgica, vol. 83, no. 3, July 2020, p. 493. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=146451558&authtype=sso&custid=ns315887.

APA

Cencini, E., Fabbri, A., Mecacci, B., & Bocchia, M. (2020). Is bendamustine plus rituximab a suitable option for rituximab-refractory duodenal-type follicular lymphoma? Acta Gastro-Enterologica Belgica, 83(3), 493.

Chicago

Cencini, E., A. Fabbri, B. Mecacci, and M. Bocchia. 2020. “Is Bendamustine plus Rituximab a Suitable Option for Rituximab-Refractory Duodenal-Type Follicular Lymphoma?” Acta Gastro-Enterologica Belgica 83 (3): 493. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=146451558&authtype=sso&custid=ns315887.